Early PCI Triggers Higher Risk in Stable Heart Failure Patients With NSTEMI
Patients who suffer a non-ST-segment elevation myocardial infarction alongside stable heart failure face a higher risk of adverse events if they undergo percutaneous coronary intervention within the first 24 hours rather than later, according to an observational study published in Catheterization & Cardiovascular Interventions. Lead author Muhammad Hanif and his colleagues at SUNY Upstate Medical University found that early intervention elevated risks at both one month and one year compared with a delayed approach.
The Trial Data Contrast
Clinical trials for broader patient groups typically support performing early PCI for high-risk NSTEMI cases, but evidence for patients with preexisting stable heart failure points in a different direction. Senior author Ankur Kalra noted that randomized clinical trial data do not favor PCI for this specific group, pointing instead to surgical revascularization options like CABG. Kalra explained that the REVIVED-BCIS2 trial showed PCI offered no advantage over guideline-directed medical therapy in patients with ischemic cardiomyopathy, whereas long-term results from the STICH trial favored surgical revascularization.
The study: retrospective multicenter cohort, 217 patients with concurrent sepsis and NSTEMI who underwent PCI. Early = <72h from MI diagnosis (n=75); delayed = >=72h (n=142). (Cardiovascular Revascularization Medicine, 2026)
The retrospective analysis examined data from the TriNetX electronic health records database, covering adults with preexisting heart failure and NSTEMI treated with PCI between 2000 and 2024. Propensity-score matching yielded 2,249 patients in the early PCI group and an equivalent cohort in the delayed group. Early intervention raised the risk of a primary composite outcome—encompassing all-cause mortality, heart failure exacerbation, recurrent myocardial infarction, and ventricular tachycardia or fibrillation—at one month with a relative risk of 1.23 and at one year with a relative risk of 1.12.
Divergent Expert Perspectives on Real-World Timing
The worse outcomes observed in the early-PCI group stemmed primarily from higher rates of myocardial infarction at both time points. Sorin Brener of NewYork-Presbyterian Brooklyn Methodist Hospital highlighted limitations in the TriNetX database, noting that identifying true heart failure diagnoses in large records can be difficult when physicians use the term loosely. Brener also questioned the inclusion of ventricular tachycardia or fibrillation in the primary composite outcome and emphasized that standard guidelines do not confer benefit to early PCI in typical NSTEMI patients unless they measure as high risk on accepted clinical scores.
Kalra maintained that real-world guidelines remain ambiguous regarding symptom-guided PCI for patients hospitalized with acute decompensated heart failure and multivessel coronary disease. He suggested that physicians frequently default to immediate PCI when surgeons rule out intervention, but the new findings indicate that clinicians have time to pause, optimize heart failure medications, and assess volume status before proceeding.
Frequently Asked Questions About NSTEMI and Heart Failure Management
What specific outcomes were measured in the study comparing early and delayed PCI?
Researchers tracked a primary composite outcome that included all-cause mortality, heart failure exacerbations, recurrent myocardial infarctions, and ventricular tachycardia or fibrillation over one-month and one-year periods.
Which specific patient groups were excluded from the TriNetX database analysis?
The retrospective study excluded pregnant individuals, along with patients presenting with acute decompensated heart failure, cardiogenic shock, and ST-segment elevation myocardial infarction.
How did researchers account for confounding variables in the patient data?
The study utilized propensity-score matching to create comparable cohorts of 2,249 patients in both the early and delayed PCI treatment groups.